Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2022

View Archived Issues

NiKang Therapeutics patents new PROTACs for cancer

Genzyme discloses new CSF-1R inhibitors

Gilead Sciences synthesizes new PADI4 inhibitors

University of California presents new CYP3A4 inhibitors

MEKanistic Therapeutics identifies new PI3K and/or EGFR inhibitors

GATA1 c.616A>C mutation tied to thrombocytopenia due to platelet formation impairment

Inosine released by apoptotic brown adipocytes regulates thermogenic fat and counteracts obesity

PAN domain regulates binding and activation of the c-MET pathway and may be an anticancer target

Novel variants in genes HPS3, HPS5 and DTNBP1 linked to Hermansky-Pudlak syndrome

Preclinical characterization of novel antileishmanial agents

PharmaCyte begins pig study to support planned clinical trial of CypCaps for pancreatic cancer

FDA clears IND for Obsidian's TIL therapy OBX-115

Sosei and Cancer Research UK agree to advance EP4 antagonist HTL-0039732 into clinic

Oncogenic collagen allows cancer cells to evade immune response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...